Advertisement
UK markets close in 6 hours 56 minutes

  • FTSE 100

    7,837.66
    -39.39 (-0.50%)
     

  • FTSE 250

    19,283.06
    -167.61 (-0.86%)
     

  • AIM

    740.81
    -4.48 (-0.60%)
     

  • GBP/EUR

    1.1677
    -0.0006 (-0.05%)
     

  • GBP/USD

    1.2437
    -0.0001 (-0.01%)
     

  • Bitcoin GBP

    51,781.41
    +2,514.30 (+5.10%)
     

  • CMC Crypto 200

    1,337.34
    +24.72 (+1.89%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • CRUDE OIL

    82.90
    +0.17 (+0.21%)
     

  • GOLD FUTURES

    2,397.00
    -1.00 (-0.04%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,699.63
    -137.77 (-0.77%)
     

  • CAC 40

    7,979.26
    -44.00 (-0.55%)
     
Money:

Best mortgage deals of the week

As possibility of multiple interest rate cuts dwindle here's what banks and building societies are offering

Former GSK CEO and ex-R&D boss move to biotech venture firms

Reuters - UK Focus

LONDON, Sept 19 (Reuters) - GlaxoSmithKline (Other OTC: GLAXF - news) 's former chief executive Andrew Witty and its one-time research head Moncef Slaoui both picked up new jobs in the biotech venture capital sector on Tuesday, following a route favoured by many ex-pharma executives.

Witty, who stepped down as head of Britain's biggest drugmaker in March, is joining U.S.-based Hatteras Venture Partners (IOB: 0QOQ.IL - news) , while Slaoui has signed up with European venture firm Medicxi, the companies said in separate statements.

At Hatteras, Witty will be working with general partner Bob (Shanghai: 601169.SS - news) Ingram, another former CEO of Glaxo. (Reporting by Ben Hirschler, editing by Louise Heavens)